title: Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients.
abstract: Along with antioxidant properties, carnitine is an important regulator of lipid metabolism in humans. While beneficial effects of carnitine have been demonstrated in animal models of Huntington's disease (HD), metabolism of carnitine has not been studied in humans with this illness. In this retrospective database review from 23 patients admitted to a HD-specialized nursing home unit, we found a relatively high prevalence of hypocarnitinemia (6 cases, 26%). Our review suggests that catabolism and chronic valproate use predisposed our patients to develop hypocarnitinemia. The patients with low serum carnitine levels who received levocarnitine supplementation, during a mean period of 7.3 months, showed improvement in motor, cognitive and behavioral measures. We hypothesize that observed improvement related to the resolution of reversible metabolic encephalopathy and myopathy associated with secondary carnitine deficiency. In conclusion, notwithstanding its limitations, this is the first study to report measurements of carnitine levels in HD patients, revealing relatively high prevalence of hypocarnitinemia in our population. Our findings suggest that HD patients with hypocarnitinemia may benefit from low-dose levocarnitine supplementation. Further studies of carnitine metabolism and supplementation in HD patients are warranted.
authors.affiliation: Department of Mental Health, University of South Carolina School of Medicine, Columbia, SC, USA. mbc20@scdmh.org
authors.forename: Miroslav
authors.initials: M
authors.lastname: Cuturic
authors.forename: Ruth K
authors.initials: RK
authors.lastname: Abramson
authors.forename: Robert R
authors.initials: RR
authors.lastname: Moran
authors.forename: James W
authors.initials: JW
authors.lastname: Hardin
authors.forename: Elaine M
authors.initials: EM
authors.lastname: Frank
authors.forename: Andrea A
authors.initials: AA
authors.lastname: Sellers
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D002331:Carnitine / Q000097:blood* / Q000172:deficiency / Q000627:therapeutic use*; D016208:Databases, Factual; D004032:Diet; D019587:Dietary Supplements; D005260:Female; D006760:Hospitalization; D006801:Humans; D006816:Huntington Disease / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D009752:Nutritional Status; D012189:Retrospective Studies; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid; D002331:Carnitine